TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32840955
Drug: Video-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-based cognitive-behavioral therapy for insomnia (VCBT-I)
Study: 32466881
Drug: Drug-Coated Balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Coated Balloon (DCB) Angioplasty
Study: 32466881
Drug: Repeat Drug-Eluting
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat Drug-Eluting Stent (DES) Implantation
Study: 32967685
Drug: Indacaterol maleate
Normalized name: Indacaterol Maleate
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol maleate 150 μg once daily (o.d.)
Study: 32967685
Drug: Indacaterol acetate
Normalized name: indacaterol acetate
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol acetate 150 μg once daily (o.d.)
Study: 39058968
Drug: Chemotherapy (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (2 cycles)
Study: 35033182
Drug: Dexamethasone 6
Normalized name: dexamethasone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 6 mg
Study: 32478922
Drug: Garlic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic supplementation (1,000 mg for 8 weeks)
Study: 32763217
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg film-coated tablets
Study: 32763217
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg film-coated tablets
Study: 32763217
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg film-coated tablets or 30 mg dispersible tablets
Study: 32763217
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg dispersible tablets or 50 mg film-coated tablets
Study: 35963559
Drug: combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined treatment and guanfacine
Study: 33452967
Drug: Curcuma longa
Normalized name: Curcuma Longa
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuma longa (1000 mg/day)
Study: 33452967
Drug: Miconia albicans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconia albicans (1000 mg/day)
Study: 616849227
Drug: Medcall lenses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medcall lenses (ML)
Study: 37349841
Drug: Pregabalin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (all doses)
Study: 33441315
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment pathway (broad-spectrum antibiotics and active observation)
Study: 33292009
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy (initially implemented)
Study: 32783238
Drug: High-proanthocyanidin cranberry
Normalized name: grape seed proanthocyanidins
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-proanthocyanidin cranberry juice (44 mg proanthocyanidin/240-mL serving) consumed twice daily for 8 weeks
Study: 34890567
Drug: Intensive high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive high-dose adalimumab plus thiopurine (160 mg adalimumab once per week for 4 weeks followed by 40 mg every 2 weeks, with escalation of dose at 4 months and 8 months if needed; initial dose of azathioprine 2·5 mg/kg or mercaptopurine 1·5 mg/kg)
Study: 34890567
Drug: Standard adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard adalimumab monotherapy (160 mg at week 0, 80 mg at week 2, then 40 mg every 2 weeks)
Study: 34890567
Drug: Intensive high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive high-dose adalimumab plus thiopurine
Study: 34890567
Drug: Standard adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard adalimumab monotherapy
Study: 35638317
Drug: Duloxetine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (maximum 60 mg/daily for 18 weeks)
Study: 33514390
Drug: Antenatal plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal plasma CMV-DNAemia of > 50 copies/mL
Study: 33514390
Drug: HIV-infected but
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-infected but non-transmitting mothers with CMV-DNAemia of > 50 copies/mL
Study: 32831069
Drug: Benznidazole 30d/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benznidazole 30d/150 mg
Study: 32831069
Drug: Benznidazole 60d/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benznidazole 60d/300 mg
Study: 33865303
Drug: 5% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% urea cream
Study: 32787905
Drug: TCM formulae
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM formulae (Tiaogan‐BuXu‐Jiedu granules) plus ETV 0.5 mg per day for 96 weeks
Study: 32787905
Drug: TCM granule
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCM granule placebo plus ETV 0.5 mg per day for 96 weeks
Study: 34784719
Drug: Functional broth
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional broth (CF) enriched with 5.6 g FOS/100 g
Study: 34784719
Drug: Control broth
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control broth (CC) with 0.4 g maltodextrin/100 g
Study: 32817358
Drug: Lacosamide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (up to 12 mg/kg/day or 400 mg/day)
Study: 34161883
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (ET) with letrozole+ribociclib
Study: 32683215
Drug: Constraint Induced
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint Induced Movement Therapy (CIMT)
Study: 33569865
Drug: MLV‐RAL 0.05%/0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLV‐RAL 0.05%/0.1% cream
Study: 33569865
Drug: Retinol 0.05%/0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinol 0.05%/0.1% cream
Study: 34980827
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of an oxygen-enriched oil-based gel, applied 3 times daily for 10 days
Study: 32101996
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy (IT)
Study: 36106379
Drug: Adjunctive perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive perampanel (≤8mg/day)
Study: 32022887
Drug: Pasireotide, 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide, 900 μg, subcutaneously twice a day for 7 days
Study: 32022887
Drug: Hydrocortisone, 100
Normalized name: Hydrocortisone, 100 mg/60 mL rectal enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone, 100 mg, intravenously 3 times a day for 3 days
Study: 34282693
Drug: Antibiotic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic administration during resuscitation
Study: 32525465
Drug: Viral load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viral load <200 copies/mL
Study: 35008040
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (AS) with 1000 IU·d‐1 natural vitamin E and 1000 mg·d‐1 vitamin C
Study: 34085467
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (EA + acupoint catgut embedding)
Study: 34419090
Drug: Oropharyngeal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal administration of colostrum (0.4 ml every 3 hours for 10 days within the first 48 hours after birth)
Study: 34259920
Drug: Azithromycin suspension
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin suspension administered twice daily by gargling for 30 seconds and swallowing, starting on the first day of chemotherapy.
Study: 34711335
Drug: Paclitaxel drug-coated
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel drug-coated devices (DCDs)
Study: 34862643
Drug: Low-Intensity Focused
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Focused Ultrasound (LIFU) treatment, power output 2.5 W/cm2, frequency 1 MHz, treating time 20 minutes
Study: 34862643
Drug: Low-Intensity Focused
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Focused Ultrasound (LIFU) treatment
Study: 34796837
Drug: Methotrexate combined
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate combined with anti-IL6 receptor (tocilizumab)
Study: 32053133
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of FOLFOX or CAPOX chemotherapy
Study: 32053133
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of FOLFOX or CAPOX chemotherapy
Study: 32053133
Drug: FOLFOX chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX chemotherapy (3 months)
Study: 32053133
Drug: CAPOX chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPOX chemotherapy (3 months)
Study: 32053133
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of chemotherapy
Study: 35762428
Drug: Kindergarten mode
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kindergarten mode treatment (test group)
Study: 34581765
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (20 μg/d)
Study: 34581765
Drug: High-protein (HP)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein (HP) yogurt (10 g protein/100 g)
Study: 34581765
Drug: Normal-protein (NP)
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-protein (NP) yogurt (3.5 g protein/100 g)
Study: 32816787
Drug: Unguided corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided corticosteroid injection
Study: 32687296
Drug: Electroneurostimulation (ENS)
Normalized name: Salazopyrin EN
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electroneurostimulation (ENS) of the cervical sympathetic ganglia combined with gymnastics of the oculomotor muscles and shoulder girdle (MG)
Study: 35854327
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) taken daily until birth
Study: 35854327
Drug: Metformin taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin taken daily until birth
Study: 32483622
Drug: Medium-dose D1
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose D1 activation (combination of levodopa and a D2 antagonist)
Study: 32483622
Drug: Low-dose D1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose D1 activation
Study: 32483622
Drug: High-dose D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose D1 activation
Study: 35192440
Drug: Client-centered occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centered occupational therapy
Study: 35192440
Drug: General occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: General occupational therapy
Study: 33591929
Drug: Psychological interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological interventions alongside analgesics or anesthetics
Study: 33248590
Drug: Chitosan oligosaccharides
Normalized name: chitosan oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan oligosaccharides (COS) supplementation at 200 mg/kg
Study: 35296254
Drug: Multiple medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple medications
Study: 33082712
Drug: Positive drugs
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive drugs
Study: 35313268
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml ropivacaine
Study: 33443859
Drug: Control (tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (tablets devoid of any scent)
Study: 34337074
Drug: Antibiotic-loaded bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-loaded bone cement repair
Study: 34337074
Drug: Conventional vacuum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional vacuum sealing draining treatment
Study: 35168586
Drug: Education program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education program with peer support on social media (Facebook Page of Antibiotic Use), 2 weekly sessions of 90 minutes each.
Study: 35168586
Drug: Education program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education program with peer support on social media (Facebook Page of Antibiotic Use).
Study: 35841016
Drug: 3% hydrogen
Normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [3% Hydrogen Peroxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% hydrogen peroxide solution
Study: 36368248
Drug: Wormwood vaginal
Normalized name: Wormwood
DrugBank: Wormwood (DB14291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wormwood vaginal gel
Study: 35366528
Drug: tACS-30 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: tACS-30 (30 min/2 mA daily sessions for 3 days)
Study: 33496330
Drug: Child Development
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child Development Agents (CDA)
Study: 35338534
Drug: 1-week massed
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week massed cognitive processing therapy (CPT) delivered virtually, twice per day for 5 days
Study: 35193056
Drug: Voucher redemption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voucher redemption or prescription for eyeglasses to be purchased on the market
Study: 35970918
Drug: 5.45% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.45% sodium chloride solution (group B)
Study: 35970918
Drug: 10% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sodium chloride solution (group C)
Study: 35970918
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride solution (group A)
Study: 35713110
Drug: 10-week internet-based
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-week internet-based cognitive-behavioral therapy (iCBT), n = 26
Study: 32164507
Drug: 177Lu-PSMA-radioligand therapy
Normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu-PSMA-radioligand therapy
Study: 36368169
Drug: Telerehabilitation (TR)
Normalized name: hyoscyamine sulfate Extended Release Oral Tablet [Hyoscyamine TR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telerehabilitation (TR) group received real-time motor-cognitive dual-task exercise treatment via video conferencing for 6 weeks
Study: 37659673
Drug: Guselkumab 200
Normalized name: guselkumab 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 200 mg
Study: 35134323
Drug: Guselkumab 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 600 mg
Study: 35134323
Drug: Guselkumab 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 1200 mg
Study: 32221178
Drug: Antidepressive medications
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressive medications plus cognitive behavioral therapy
Study: 32221178
Drug: Antidepressive medications
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressive medications plus dynamic psychotherapy
Study: 32221178
Drug: Antidepressive medications
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressive medications plus psychotherapy (both types)
Study: 34190962
Drug: Zuranolone, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuranolone, 30 mg, administered orally each evening for 2 weeks
Study: 34190962
Drug: Zuranolone, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuranolone, 30 mg
Study: 36424687
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical glucose tablets)
Study: 34690065
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg daily for 3 months
Study: 36347450
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (GT) supplementation (738 mg)
Study: 33025645
Drug: 6-mm implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mm implants
Study: 33025645
Drug: 11-mm implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-mm implants
Study: 34538253
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (individual occupational therapy)
Study: 32853384
Drug: Lattice radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lattice radiation therapy (LRT) with a dose of 24 Gy in three fractions, followed by conventionally fractionated external beam irradiation to 44.28 Gy
Study: 33338415
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (1000 mg) administered via intramuscular injection at baseline, 6 weeks, and then every 3 months for 2 years.
Study: 33338415
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via intramuscular injection at baseline, 6 weeks, and then every 3 months for 2 years.
Study: 33338415
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (1000 mg) administered via intramuscular injection.
Study: 33338415
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via intramuscular injection.
Study: 32147751
Drug: MOP1 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOP1 group received 3 MOPs on the buccal surface of alveolar bone
Study: 32147751
Drug: MOP2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOP2 group received 3 buccal MOPs and 3 palatal MOPs
Study: 32134956
Drug: Naltrexone (NTX)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone (NTX) 50 mg daily
Study: 35381069
Drug: Daily prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily prednisone (0.75 mg/kg)
Study: 35381069
Drug: Daily deflazacort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily deflazacort (0.90 mg/kg)
Study: 35381069
Drug: Intermittent prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent prednisone (0.75 mg/kg for 10 days on and then 10 days off)
Study: 32587591
Drug: PD-1/PD-L1 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 inhibitors
Study: 35493119
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg plus standard of care (SOC)
Study: 33159336
Drug: New Forest
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Forest Parenting Programme (NFPP‐SH) + Treatment as Usual (TAU)
Study: 34636914
Drug: 3A-HBV (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3A-HBV (10 μg)
Study: 36380220
Drug: Cannabis with
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis with 0 mg CBD (0:1 CBD:THC)
Study: 36380220
Drug: Cannabis with
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis with 10 mg CBD (1:1 CBD:THC)
Study: 36380220
Drug: Cannabis with
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis with 20 mg CBD (2:1 CBD:THC)
Study: 36380220
Drug: Cannabis with
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis with 30 mg CBD (3:1 CBD:THC)
Study: 32054315
Drug: Pivotal response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pivotal response treatment package
Study: 35130850
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (0.1%) combined with rhEGF (20 μg/ml)
Study: 34393800
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no corticosteroid treatment)
Study: 36443712
Drug: Dialectical Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavioral Therapy-based group treatment (DBT-bGT)
Study: 33930527
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment (hazard ratio equals 0.7)
Study: 34975830
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (500 mg daily for 14 days)
Study: 35796695
Drug: Eriomin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eriomin (200 mg/d for 12 weeks)
Study: 35367955
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy with a Well‐Being focus
Study: 35367955
Drug: Mindfulness Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness Based Cognitive Therapy
Study: 35029706
Drug: CBD 300
Normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (SYNTHETIC) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD 3000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD 300 mg
Study: 39234619
Drug: Antipsychotic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medications
Study: 33629525
Drug: Baerveldt implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baerveldt implant (BGI)